

MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE
Recommendations Summary
May 13, 2015

In Attendance:

	Committee Member	Yes or No
1	Rosanne Barber	Yes
2	James Boblin M.D.	Yes
3	Ward Brown, M.D.	Yes
4	Catherine Decker Pharm.D.	Yes
5	Ronald Diamond, M.D.	Yes- Left at 12:35PM
6	John J. W. Fangman, M.D.	Yes
7	Lawrence Fleming M.D.	Yes
8	Kevin Izard M.D.	Yes-Arrived at 12:30PM
9	Steve Maike RPh	Yes-Arrived at 11:10AM
10	William E. Raduege, M.D.	Yes
11	Pat Towers	Yes
12	Alicia Walker Pharm.D.	Yes
13	Michael Witkovsky M.D.	Yes-Arrived at 10:05AM

MAY 2015 THERAPEUTIC DRUG CLASS

ANGIOTENSIN MODULATORS
ANGIOTENSIN MODULATOR COMBINATIONS
BETA BLOCKERS
CALCIUM CHANNEL BLOCKERS
LIPOTROPICS, OTHER
LIPOTROPICS, STATINS
PAH AGENTS, ORAL AND INHALED
ANTICOAGULANTS
PLATELET AGGREGATION INHIBITORS
HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
HYPOGLYCEMICS, INSULIN AND RELATED AGENTS
HYPOGLYCEMICS, MEGLITINIDES
HYPOGLYCEMICS, OTHER
HYPOGLYCEMICS, SULFONYLUREAS
HYPOGLYCEMICS, TZD
ANTIEMETIC/ANTIVERTIGO AGENTS
PANCREATIC ENZYMES
PROTON PUMP INHIBITORS
ULCERATIVE COLITIS AGENTS
H. PYLORI TREATMENT
ANTIBIOTICS, GI
ANTIBIOTICS, INHALED
ANTIBIOTICS, VAGINAL
ANTIFUNGALS, ORAL
ANTIVIRALS, ORAL
CEPHALOSPORINS AND RELATED AGENTS
PENICILLINS
FLUOROQUINOLONES, ORAL
MACROLIDES/KETOLIDES
TETRACYCLINES
ACNE AGENTS, TOPICAL
ANTIBIOTICS, TOPICAL
ANTIFUNGALS, TOPICAL
ANTIPARASITICS, TOPICAL
ANTIVIRALS, TOPICAL
ANALGESICS, MISCELLANEOUS
ANALGESICS, NARCOTICS LONG
ANALGESICS, NARCOTICS SHORT
OPIATE DEPENDENCY
ANTIMIGRAINE AGENTS
SKELETAL MUSCLE RELAXANTS
BLADDER RELAXANT PREPARATIONS
BONE RESORPTION SUPPRESSION AND RELATED AGENTS
ERYTHROPOIESIS STIMULATING PROTEINS
GROWTH HORMONE
ANDROGENIC AGENTS
BPH TREATMENTS
PHOSPHATE BINDERS
HEPATITIS B AGENTS
HEPATITIS C AGENTS
MULTIPLE SCLEROSIS AGENTS
GI MOTILITY CHRONIC

Recommendations Summary:

ANGIOTENSIN MODULATORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
LISINOPRIL HCTZ (ORAL)	11.7%	ON	Yes-Generic			
QUINAPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
ENALAPRIL HCTZ (ORAL)	0.3%	ON	Yes-Generic			
MOEXIPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
FOSINOPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
CAPTROPRI HCTZ (ORAL)	0.0%	OFF	No-Generic			
BENAZEPRIL HCTZ (ORAL)	0.0%	OFF	No-Generic			
LISINOPRIL (ORAL)	47.6%	ON	Yes-Generic			
BENAZEPRIL (ORAL)	3.1%	ON	Yes-Generic			
RAMIPRIL (ORAL)	0.4%	ON	Yes-Generic			
FOSINOPRIL (ORAL)	0.1%	ON	Yes-Generic			
QUINAPRIL (ORAL)	0.0%	OFF	No-Generic			
ENALAPRIL (ORAL)	5.0%	ON	Yes-Generic			
TRANDOLAPRIL (ORAL)	0.0%	OFF	No-Generic			
PERINDOPRIL (ORAL)	0.0%	OFF	No-Generic			
MOEXIPRIL (ORAL)	0.0%	OFF	No-Generic			
CAPTROPRI (ORAL)	0.4%	ON	Yes-Generic			
EPANED (ORAL)	0.2%	OFF	No			
VALSARTAN (AG) (ORAL)	0.0%	ON	Yes-Generic			
MICARDIS (ORAL)	0.0%	OFF	No			
BENICAR (ORAL)	0.2%	OFF	No			
LOSARTAN (ORAL)	18.2%	ON	Yes-Generic			
IRBESARTAN (ORAL)	0.1%	OFF	No-Generic			
EDARBI (ORAL)	0.0%	OFF	No			
VALSARTAN (ORAL)	5.0%	ON	Yes-Generic			
TEVETEN (ORAL)	0.0%	OFF	No			
ATACAND (ORAL)	0.0%	OFF	No			
EPROSARTAN (ORAL)	0.0%	OFF	No-Generic			
CANDESARTAN (AG) (ORAL)	0.0%	OFF	No-Generic			
CANDESARTAN (ORAL)	0.0%	OFF	No-Generic			
TELMISARTAN (AG) (ORAL)	0.0%	OFF	No-Generic			
TELMISARTAN (ORAL)	0.0%	OFF	No-Generic			
MICARDIS HCT (ORAL)	0.0%	OFF	No			
BENICAR HCT (ORAL)	0.2%	OFF	No			
IRBESARTAN HCTZ (ORAL)	0.0%	OFF	No-Generic			
LOSARTAN HCTZ (ORAL)	5.5%	ON	Yes-Generic			
EDARBYCLOR (ORAL)	0.0%	OFF	No			
TEVETEN HCT (ORAL)	0.0%	OFF	No			
DIOVAN HCT (ORAL)	1.6%	ON	Yes			
ATACAND HCT (ORAL)	0.0%	OFF	No			
VALSARTAN HCTZ (ORAL)	0.0%	OFF	No-Generic			
TELMISARTAN HCTZ (AG) (ORAL)	0.0%	OFF	No-Generic			
CANDESARTAN HCTZ (ORAL)	0.0%	OFF	No-Generic			
TELMISARTAN HCTZ (ORAL)	0.0%	OFF	No-Generic			
TEKTURNA (ORAL)	0.1%	OFF	No			
TEKTURNA HCT (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - 10 members were in favor of the motion. Alicia Walker abstained. James Boblin not present.
 - Motion passes

ANGIOTENSIN MODULATOR COMBINATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZOR (ORAL)	37.2%	ON	Yes			
EXFORGE (ORAL)	16.0%	ON	Yes			
EXFORGE HCT (ORAL)	7.6%	ON	Yes			
TRIBENZOR (ORAL)	26.5%	ON	Yes			
TARKA (ORAL)	0.9%	ON	Yes			
AMLODIPINE / BENAZEPRIL (ORAL)	8.0%	ON	Yes-Generic			
AMTURNIDE (ORAL)	0.0%	OFF	No			
TEKAMLO (ORAL)	0.0%	OFF	No			
TWYNSTA (ORAL)	0.0%	OFF	No			
TRANDOLAPRIL / VERAPAMIL (AG) (ORAL)	0.0%	NR	No-Generic			
TELMISARTAN / AMLODIPINE (ORAL)	0.0%	OFF	No-Generic			
AMLODIPINE / VALSARTAN / HCTZ (AG) (ORAL)	0.1%	NR	No-Generic			
TRANDOLAPRIL / VERAPAMIL (ORAL)	0.0%	OFF	No-Generic			
AMLODIPINE / VALSARTAN (ORAL)	2.8%	NR	No-Generic			
AMLODIPINE / VALSARTAN / HCTZ (ORAL)	1.0%	NR	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - 10 members were in favor of the motion. Alicia Walker abstained. James Boblin not present.
 - Motion passes

BETA-BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BISOPROLOL HCTZ (ORAL)	0.3%	ON	Yes-Generic			
DUTOPROL (ORAL)	0.0%	OFF	No			
LOPRESSOR HCT (ORAL)	0.0%	OFF	No			
PROPRANOLOL / HCTZ (ORAL)	0.0%	OFF	No-Generic			
ATENOLOL / CHLOROTHALIDONE (ORAL)	1.0%	ON	Yes-Generic			
METOPROLOL / HCTZ (ORAL)	0.0%	OFF	No-Generic			
NADOLOL / BENDROFLUMETHIAZIDE (ORAL)	0.0%	OFF	No-Generic			
ATENOLOL (ORAL)	17.3%	ON	Yes-Generic			
METOPROLOL (ORAL)	28.5%	ON	Yes-Generic			
CARVEDILOL (ORAL)	11.9%	ON	Yes-Generic			
PROPRANOLOL TABLET (ORAL)	6.1%	ON	Yes-Generic			
PROPRANOLOL SOLUTION (ORAL)	0.4%	ON	Yes-Generic			
LEVATOL (ORAL)	0.0%	OFF	No			
SOTALOL (ORAL)	0.7%	ON	Yes-Generic			
BYSTOLIC (ORAL)	1.3%	OFF	No			
ACEBUTOLOL (ORAL)	0.1%	ON	No-Generic			
BISOPROLOL (ORAL)	0.3%	ON	Yes-Generic			
INDERAL XL (ORAL)	0.0%	OFF	No			
BETAXOLOL (ORAL)	0.0%	OFF	No-Generic			
METOPROLOL XL (ORAL)	27.8%	ON	Yes-Generic			
PINDOLOL (ORAL)	0.0%	OFF	No-Generic			
INNOPRAN XL (ORAL)	0.0%	OFF	No			
LABELALOL (ORAL)	0.9%	OFF	Yes-Generic			
COREG CR (ORAL)	0.1%	OFF	No			
PROPRANOLOL ER (ORAL)	3.0%	ON	Yes-Generic			
TIMOLOL (ORAL)	0.0%	OFF	No-Generic			
NADOLOL (ORAL)	0.3%	OFF	No-Generic			
HEMANGEOL (ORAL)	0.0%	OFF	No			
SOTYLIZE (ORAL)	0.0%	NR	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - 10 members were in favor of the motion. Alicia Walker abstained. James Boblin not present.
 - Motion passes

CALCIUM CHANNEL BLOCKERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMLODIPINE (ORAL)	71.8%	ON	Yes-Generic			
ISRADIPINE (ORAL)	0.1%	OFF	No-Generic			
NIFEDIPINE ER (ORAL)	5.4%	ON	Yes-Generic			
FELODIPINE ER (ORAL)	0.1%	OFF	No-Generic			
NIFEDIPINE IR (ORAL)	0.3%	ON	Yes-Generic			
NISOLDIPINE (ORAL)	0.0%	OFF	No-Generic			
NICARDIPINE (ORAL)	0.0%	OFF	No-Generic			
NIMODIPINE (ORAL)	0.0%	ON	Yes-Generic			
NYMALIZE (ORAL)	0.0%	OFF	No			
VERAPAMIL TABLET (ORAL)	1.2%	ON	Yes-Generic			
VERAPAMIL TABLET ER (ORAL)	3.5%	ON	Yes-Generic			
DILTIAZEM TABLET (ORAL)	1.4%	ON	Yes-Generic			
DILTIAZEM CAPSULE ER (ORAL)	14.7%	NR	Yes-Generic			
CARDIZEM LA (ORAL)	0.2%	ON	Yes			
VERAPAMIL CAPSULE ER (ORAL)	1.2%	ON	Yes-Generic			
DILTIAZEM LA (AG) (ORAL)	0.0%	OFF	No-Generic			
MATZIM LA (ORAL)	0.0%	OFF	No-Generic			
VERAPAMIL 360 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
VERAPAMIL ER PM (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion passes

LIPOTROPICS, OTHER						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WELCHOL TABLET (ORAL)	1.5%	OFF	No			
COLESTIPOL TABLET (ORAL)	1.5%	ON	Yes-Generic			
WELCHOL POWDER PACK (ORAL)	0.3%	OFF	No			
COLESTID GRANULES (ORAL)	0.0%	OFF	No			
CHOLESTYRAMINE/ASPARTAME (ORAL)	2.3%	ON	Yes-Generic			
COLESTIPOL GRANULES (ORAL)	0.0%	OFF	No-Generic			
CHOLESTYRAMINE/SUCROSE (ORAL)	4.2%	ON	Yes-Generic			
TRIGLIDE (ORAL)	0.0%	OFF	No			
FENOFIBRATE TABLET (AG) (TRICOR) (ORAL)	13.5%	ON	No-Generic			
GEMFIBROZIL (ORAL)	13.9%	ON	Yes-Generic			
TRILIPIX (ORAL)	5.6%	ON	Yes			
TRICOR (ORAL)	3.4%	OFF	Yes			
FENOFIBRATE TABLET (TRICOR) (ORAL)	9.0%	ON	No-Generic			
FENOFIBRATE CAPSULE (LIPOFEN) (ORAL)	0.0%	OFF	No-Generic			
ZETIA (ORAL)	12.8%	OFF	No			
LIPOFEN (ORAL)	0.0%	OFF	No			
FENOFIBRIC ACID (FIBRICOR) (ORAL)	0.0%	OFF	No-Generic			
FENOGLIDE (ORAL)	0.1%	OFF	No-Generic			
FENOFIBRATE TABLET (LOFIBRA) (ORAL)	17.2%	ON	No-Generic			
LOVAZA (ORAL)	0.7%	ON	Yes			
FENOFIBRATE CAPSULE (LOFIBRA) (ORAL)	0.5%	OFF	No-Generic			
FENOFIBRIC ACID (TRILIPIX) (AG) (ORAL)	0.0%	OFF	No-Generic			
VASCEPA (ORAL)	0.0%	OFF	No			
FENOFIBRATE (ANTARA) (AG) (ORAL)	0.0%	OFF	No-Generic			
ANTARA (ORAL)	0.0%	OFF	No			
FENOFIBRATE (ANTARA) (ORAL)	0.0%	OFF	No-Generic			
FENOFIBRIC ACID (TRILIPIX) (ORAL)	0.0%	OFF	No-Generic			
OMEGA-3 ACID ETHYL ESTERS (ORAL)	0.4%	NR	No-Generic			
KYNAMRO (SUBCUTANE.)	0.0%	OFF	No			
JUXTAPID (ORAL)	0.0%	OFF	No			
NIACOR (ORAL)	0.0%	ON	Yes-Generic			
NIASPAN (ORAL)	13.0%	ON	Yes			
NIACIN ER (ORAL)	0.1%	OFF	No-Generic			

- Discussion: Catherine Decker questioned if we will be alerting the pharmacies of brands that will replace generics. Kimberly Smithers noted that the pharmacies will be notified by a ForwardHealth Provider Update and updated Preferred Drug List.
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion passes

LIPOTROPICS, STATINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SIMVASTATIN (ORAL)	33.5%	ON	Yes-Generic			
VYTORIN (ORAL)	0.2%	OFF	No			
CRESTOR (ORAL)	5.0%	OFF	No			
LOVASTATIN (ORAL)	7.3%	ON	Yes-Generic			
ALTOPREV (ORAL)	0.0%	OFF	No			
ATORVASTATIN (ORAL)	38.9%	ON	Yes-Generic			
LESCOL (ORAL)	0.0%	OFF	No			
LESCOL XL (ORAL)	0.1%	OFF	No			
PRAVASTATIN (ORAL)	14.9%	ON	Yes-Generic			
ADVICOR (ORAL)	0.0%	OFF	No			
SIMCOR (ORAL)	0.0%	OFF	No			
LIPTRUZET (ORAL)	0.0%	OFF	No			
LIVALO (ORAL)	0.1%	OFF	No			
FLUVASTATIN (ORAL)	0.1%	OFF	No-Generic			
AMLODIPINE-ATORVASTATIN (ORAL)	0.0%	OFF	No-Generic			
CADUET (ORAL)	0.0%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion passes

PAH AGENTS, ORAL AND INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TYVASO (INHALATION)	4.5%	OFF	No			
VENTAVIS (INHALATION)	1.6%	OFF	No			
TRACLEER (ORAL)	17.7%	ON	Yes			
LETAIRIS (ORAL)	9.4%	ON	Yes			
OPSUMIT (ORAL)	1.6%	OFF	No			
SILDENAFIL (ORAL)	42.4%	ON	Yes-Generic			
ADCIRCA (ORAL)	15.5%	OFF	No			
ORENITRAM ER (ORAL)	2.5%	NR	No			
REVATIO SUSPENSION (ORAL)	0.0%	NR	No			
ADEMPAS (ORAL)	4.9%	OFF	No			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion passes

ANTICOAGULANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
WARFARIN (ORAL)	75.8%	ON	Yes-Generic			
XARELTO (ORAL)	10.8%	ON	Yes			
PRADAXA (ORAL)	2.1%	ON	Yes			
ELIQUIS (ORAL)	2.2%	ON	Yes			
SAVAYSA (ORAL)	0.0%	NR	No			
XARELTO DOSE PACK (ORAL)	0.0%	NR	Yes			
FRAGMIN DISP SYRIN (SUBCUTANE.)	0.1%	ON	Yes			
ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANEOUS)	0.1%	ON	Yes-Generic			
ENOXAPARIN SODIUM VIAL (SUBCUTANEOUS)	0.1%	ON	Yes-Generic			
ENOXAPARIN SYRINGE (SUBCUTANE.)	4.3%	ON	Yes-Generic			
ENOXAPARIN SYRINGE (AG) (SUBCUTANE.)	4.3%	ON	Yes-Generic			
ARIXTRA (SUBCUTANE.)	0.0%	OFF	No			
FONDAPARINUX (SUBCUTANE.)	0.1%	OFF	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-William Radeuge
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion passes

PLATELET AGGREGATION INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CLOPIDOGREL (ORAL)	90.7%	ON	Yes-Generic			
AGGRENOX (ORAL)	6.3%	ON	Yes			
DIPYRIDAMOLE (ORAL)	0.4%	ON	Yes-Generic			
BRILINTA (ORAL)	1.0%	OFF	No			
TICLOPIDINE (ORAL)	0.1%	OFF	No-Generic			
EFFIENT (ORAL)	1.5%	OFF	No			
ZONTIVITY (ORAL)	0.0%	NR	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GLYSET (ORAL)	4.6%	ON	Yes			
ACARBOSE (ORAL)	95.4%	ON	Yes-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Lawrence Fleming
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TRADJENTA (ORAL)	11.6%	ON	Yes			
JENTADUETO (ORAL)	2.4%	ON	Yes			
KAZANO (ORAL)	0.0%	OFF	No			
JANUMET XR (ORAL)	4.0%	ON	Yes			
JANUVIA (ORAL)	60.8%	ON	Yes			
ONGLYZA (ORAL)	1.4%	OFF	No			
JANUMET (ORAL)	14.4%	ON	Yes			
KOMBIGLYZE XR (ORAL)	0.2%	OFF	No			
OSENI (ORAL)	0.1%	OFF	No			
NESINA (ORAL)	0.0%	OFF	No			
GLYXAMBI (ORAL)	0.0%	NR	No			
SYMLIN PENS (SUBCUTANE.)	0.1%	OFF	No			
BYETTA PENS (SUBCUTANE.)	3.6%	ON	Yes			
BYDUREON (SUBCUTANE.)	0.0%	OFF	Yes			
BYDUREON PENS (SUBCUTANE.)	0.0%	NR	Yes			
TANZEUM (SUBCUTANE.)	0.0%	NR	Yes			
VICTOZA (SUBCUTANE.)	1.2%	OFF	No			
TRULICITY (SUBCUTANE.)	0.0%	NR	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HYPOGLYCEMICS, INSULIN AND RELATED AGENTS

Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
HUMULIN 70/30 VIAL OTC (SUBCUTANE.)	2.7%	ON	Yes			
HUMALOG MIX VIAL (SUBCUTANE.)	0.8%	ON	Yes			
HUMULIN VIAL OTC (SUBCUTANE.)	4.2%	ON	Yes			
NOVOLOG MIX VIAL (SUBCUTANE.)	0.0%	OFF	No			
NOVOLOG MIX PEN (SUBCUTANE.)	0.1%	OFF	No			
HUMALOG MIX PEN (SUBCUTANE.)	2.9%	ON	Yes			
HUMULIN 500 U/M VIAL (SUBCUTANE.)	0.7%	ON	Yes			
NOVOLIN 70/30 VIAL OTC (SUBCUTANE.)	0.1%	OFF	No			
NOVOLIN VIAL OTC (SUBCUTANE.)	0.0%	OFF	No			
HUMULIN PEN OTC (SUBCUTANE.)	1.1%	ON	Yes			
HUMULIN 70/30 PEN OTC (SUBCUTANE.)	1.9%	ON	Yes			
LEVEMIR PENS (SUBCUTANE.)	3.5%	ON	Yes			
LANTUS VIAL (SUBCUTANE.)	12.8%	ON	Yes			
LANTUS SOLOSTAR PEN (SUBCUTANE.)	33.3%	ON	Yes			
LEVEMIR VIAL (SUBCUTANE.)	0.9%	ON	Yes			
TOUJEO SOLOSTAR PEN (SUBCUTANE.)	0.0%	NR	No			
HUMALOG VIAL (SUBCUTANE.)	10.7%	ON	Yes			
APIDRA VIAL (SUBCUTANE.)	0.1%	OFF	No			
APIDRA SOLOSTAR PEN (SUB-Q)	0.1%	OFF	No			
NOVOLOG VIAL (SUBCUTANE.)	0.2%	OFF	No			
NOVOLOG CARTRIDGE (SUBCUTANE.)	0.1%	OFF	No			
NOVOLOG PEN (SUBCUTANE.)	0.3%	OFF	No			
HUMALOG PEN (SUBCUTANE.)	21.4%	ON	Yes			
HUMALOG CARTRIDGE (SUBCUTANE.)	2.3%	ON	Yes			
AFREZZA CARTRIDGE (INHALATION)	0.0%	NR	No			

- Discussion: Kevin Izard requested clarification that if a member refused to use injectable insulin and wanted to go on Affrezza, what would the process be? He indicated that some people need insulin but will not use injections. Rick Pope stated that Affrezza is a rapid acting product and the member would still require basal insulin, which would require injections. Alicia Walker wanted to know if there were diagnosis restrictions. Kimberly Smithers stated that there is not a diagnosis restriction on these products.
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 10 members were in favor of the motion. Alicia Walker abstained. Kevin Izard opposed the motion.
 - Motion Passes

HYPOGLYCEMICS, MEGLITINIDES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PRANDIN (ORAL)	88.1%	ON	Yes			
REPAGLINIDE (ORAL)	2.0%	OFF	No-Generic			
PRANDIMET (ORAL)	0.0%	OFF	No			
NATEGLINIDE (ORAL)	9.8%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HYPOGLYCEMICS, METFORMINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METFORMIN (ORAL)	75.2%	ON	Yes-Generic			
METFORMIN ER (GLUCOPHAGE XR) (ORAL)	22.3%	ON	Yes-Generic			
GLYBURIDE-METFORMIN (ORAL)	1.5%	ON	Yes-Generic			
RIOMET (ORAL)	0.2%	ON	Yes			
GLIPIZIDE-METFORMIN (ORAL)	0.5%	ON	Yes-Generic			
METFORMIN ER (FORTAMET) (ORAL)	0.3%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HYPOGLYCEMICS, SGLT2						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
INVOKANA (ORAL)	81.5%	OFF	Yes			
FARXIGA (ORAL)	16.1%	OFF	No			
XIGDUO XR (ORAL)	0.0%	OFF	No			
INVOKAMET (ORAL)	0.0%	NR	No			
JARDIANCE (ORAL)	2.4%	NR	No			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second-Pat Towers
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HYPOGLYCEMICS, SULFONYLUREAS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
GLIMEPIRIDE (ORAL)	29.0%	ON	Yes-Generic			
GLIPIZIDE (ORAL)	32.6%	ON	Yes-Generic			
GLYBURIDE MICRONIZED (ORAL)	0.6%	ON	Yes-Generic			
GLIPIZIDE ER (ORAL)	20.9%	ON	Yes-Generic			
GLYBURIDE (ORAL)	16.9%	ON	Yes-Generic			
CHLORPROPAMIDE (ORAL)	0.0%	ON	Yes-Generic			
TOLBUTAMIDE (ORAL)	0.0%	OFF	No-Generic			
TOLAZAMIDE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HYPOGLYCEMICS, TZD						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PIOGLITAZONE (ORAL)	99.7%	ON	Yes-Generic			
ACTOPLUS MET (ORAL)	0.0%	OFF	No			
DUETACT (ORAL)	0.0%	OFF	No			
AVANDAMET (ORAL)	0.0%	OFF	No			
AVANDIA (ORAL)	0.0%	OFF	No			
AVANDARYL (ORAL)	0.0%	OFF	No			
ACTOPLUS MET XR (ORAL)	0.0%	OFF	No			
PIOGLITAZONE / METFORMIN (ORAL)	0.3%	OFF	No-Generic			
PIOGLITAZONE/GLIMEPIRIDE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIEMETIC/ANTIVERTIGO AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PROCHLORPERAZINE (ORAL)		5.1%	ON	Yes-Generic		
PROMETHAZINE SYRUP (ORAL)		1.7%	ON	Yes-Generic		
MECLIZINE OTC (ORAL)		1.6%	ON	Yes-Generic		
METOCLOPRAMIDE TABLET (ORAL)		9.5%	ON	Yes-Generic		
PROMETHAZINE TABLET (ORAL)		5.2%	ON	Yes-Generic		
ONDANSETRON ODT (ORAL)		43.4%	ON	Yes-Generic		
MECLIZINE (ORAL)		6.8%	ON	Yes-Generic		
ONDANSETRON TABLETS (ORAL)		22.4%	ON	Yes-Generic		
METOCLOPRAMIDE SOLUTION (ORAL)		0.5%	ON	Yes-Generic		
TRANSDERM-SCOP (TRANSDERM)		1.9%	ON	Yes		
ONDANSETRON SOLUTION (ORAL)		0.7%	ON	Yes-Generic		
METOZOLV ODT (ORAL)		0.0%	OFF	No		
DICLEGIS (ORAL)		0.2%	OFF	No	Yes/Dx Restricted	Yes
TRIMETHOBENZAMIDE (ORAL)		0.0%	ON	Yes-Generic		
PROCHLORPERAZINE (RECTAL)		0.2%	ON	Yes-Generic		
PROMETHAZINE 50 MG (RECTAL)		0.0%	ON	Yes-Generic		
GRANISETRON (ORAL)		0.1%	OFF	No-Generic		
EMEND (ORAL)		0.1%	ON	Yes		
PROMETHAZINE (RECTAL)		0.6%	ON	Yes-Generic		
ANZEMET (ORAL)		0.0%	OFF	No		
EMEND PACK (ORAL)		0.1%	ON	Yes		
ZUPLENZ (ORAL)		0.0%	OFF	No		
AKYNZEO (ORAL)		0.0%	NR	No		
SANCUSO (TRANSDERMAL)		0.0%	OFF	No		
DRONABINOL (ORAL)		0.0%	OFF	Yes-Generic		
CESAMET (ORAL)		0.0%	OFF	No		
MARINOL (ORAL)		0.0%	ON	No		

Discussion: James Boblin suggested adding Diclegis as a preferred drug. He stated since it is a pregnancy Category A, it should be preferred. He believed Dr. Rogers' testimony made good points about why the drug should be preferred and that it is a limited course of treatment. Kevin Izard indicated that we should make Dicelgis preferred only for pregnancy induced hyperemesis, which is more restricted than pregnancy. Hyperemesis gravidarum is a serious issue, where members may need IVs, hospitalizations, etc. Roseanne Barber stated that Diclegis should be preferred as it is less expensive than an emergency room visit and rural members are less likely to have access to an emergency room. Alicia Walker indicated that there is some likelihood that a pharmacy may not carry the product, plus it is comprised of two over the counter ingredients. Alicia asked if Vitamin B6 is a covered product. Lynn Radmer added that B6 is not a covered product and the OTC components are immediate release whereas Diclegis is an extended release product. Kevin Izard indicated that the two ingredients are available OTC. James Boblin would like to prefer Diclegis with restrictions for hyperemesis. Lynn Radmer added clarification that Dicelgis being preferred with diagnosis restriction would require the prescriber to give the diagnosis to the pharmacy. This could be viewed by prescribers as still presenting a hurdle. Kimberly Smithers stated that we can use diagnosis restrictions but no step edits. Diagnosis restrictions work on the claim and do not require a PA. Rick Pope added that by making Dicelgis diagnosis restricted we would be disqualifying any supplemental rebate for the product.

Motion 1:

- Kevin Izard made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - Motion was withdrawn after discussion

Motion 2:

- James Boblin made a motion to accept staff recommendations, but to have Diclegis as preferred with a restriction of hyperemesis gravidarum.
 - Second-Pat Towers
 - 9 members were in favor of the motion. Alicia Walker abstained. Michael Witkovsky and Steve Maike opposed the motion.
 - Motion Passes

PANCREATIC ENZYMES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PANCRELIPASE (AG) (ORAL)	22.1%	ON	Yes			
ZENPEP (ORAL)	44.7%	ON	Yes			
VIOKACE (ORAL)	0.8%	OFF	No			
CREON (ORAL)	29.0%	OFF	No			
PANCREAZE (ORAL)	2.9%	OFF	No			
ULTRESA (ORAL)	0.0%	OFF	No			
PERTZYE (ORAL)	0.5%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-John Fangman
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

PROTON PUMP INHIBITORS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OMEPRAZOLE (ORAL)	70.3%	ON	Yes-Generic			
PROTONIX SUSPENSION (ORAL)	0.2%	ON	Yes			
PANTOPRAZOLE (ORAL)	19.2%	ON	Yes-Generic			
NEXIUM (ORAL)	1.8%	OFF	No			
NEXIUM SUSPENSION (ORAL)	0.2%	ON	Yes			
LANSOPRAZOLE CAPSULES (ORAL)	0.9%	OFF	Yes-Generic			
DEXILANT (ORAL)	0.4%	OFF	No			
ESOMEPRAZOLE STRONTIUM (ORAL)	0.0%	NR	No-Generic			
RABEPRAZOLE TABLETS (ORAL)	6.5%	ON	No-Generic			
PREVACID SOLUTAB (ORAL)	0.4%	OFF	No			
OMEPRAZOLE / SODIUM BICARBONATE (ORAL)	0.0%	OFF	No-Generic			
PRILOSEC SUSPENSION (ORAL)	0.1%	ON	Yes			
ACIPHEX SPRINKLE (ORAL)	0.0%	OFF	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ULCERATIVE COLITIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DIPENTUM (ORAL)	0.3%	OFF	No			
SULFASALAZINE (ORAL)	19.5%	ON	Yes -Generic			
SULFASALAZINE DR (ORAL)	4.5%	ON	Yes -Generic			
DELZICOL (ORAL)	1.1%	OFF	No			
APRISO (ORAL)	16.3%	ON	Yes			
PENTASA (ORAL)	5.2%	OFF	No			
LIALDA (ORAL)	36.4%	ON	Yes			
BALSALAZIDE (ORAL)	8.2%	ON	Yes -Generic			
GIAZO (ORAL)	0.0%	OFF	No			
ASACOL HD (ORAL)	3.4%	OFF	No			
UCERIS (ORAL)	1.0%	OFF	No			
ROWASA (RECTAL)	1.1%	ON	Yes			
CANASA (RECTAL)	3.0%	ON	Yes			
UCERIS (RECTAL)	0.0%	OFF	No			
MESALAMINE (RECTAL)	0.0%	OFF	No-Generic			
MESALAMINE KIT (RECTAL)	0.1%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-John Fangman
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

H. PYLORI TREATMENT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PYLERA (ORAL)	3.8%	OFF	No			
HELIDAC (ORAL)	1.3%	ON	Yes			
OMECLAMOX-PAK (ORAL)	0.0%	OFF	No			
PREVPAC (ORAL)	93.8%	ON	Yes			
LANSOPRAZOLE/AMOXICILLIN/CLARITHROMYCIN (ORA)	1.3%	OFF	No-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIBIOTICS, GI						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METRONIDAZOLE TABLET (ORAL)	95.5%	ON	Yes -Generic			
NEOMYCIN (ORAL)	0.6%	ON	Yes -Generic			
TINIDAZOLE (ORAL)	0.1%	OFF	No-Generic			
TINDAMAX (ORAL)	0.0%	OFF	No			
ALINIA SUSPENSION (ORAL)	0.1%	ON	Yes			
METRONIDAZOLE CAPSULE (ORAL)	0.0%	OFF	No-Generic			
FLAGYL ER (ORAL)	0.0%	OFF	No			
ALINIA TABLET (ORAL)	0.1%	ON	Yes			
VANCOMYCIN HCL (ORAL)	0.5%	ON	Yes -Generic			
XIFAXAN (ORAL)	2.9%	OFF	No			
DIFICID TABLET (ORAL)	0.1%	OFF	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-Roseanne Barber
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIBIOTICS, INHALED						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
KITABIS PAK (INHALATION)	0.0%	NR	Yes			
BETHKIS (INHALATION)	0.9%	ON	Yes			
TOBI (INHALATION)	92.5%	ON	No			
TOBRAMYCIN SOLUTION (AG) (INHALATION)	0.0%	OFF	No-Generic			
TOBI PODHALER (INHALATION)	0.0%	OFF	No			
CAYSTON (INHALATION)	6.5%	OFF	No			
TOBRAMYCIN SOLUTION (INHALATION)	0.0%	NR	No-Generic			

- Discussion: Catherine Decker stated she was looking forward to the continuous alternating therapy (CAT) data coming out.
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIBIOTICS, VAGINAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
VANDAZOLE (VAGINAL)	2.5%	ON	Yes			
METRONIDAZOLE (VAGINAL)	86.2%	ON	Yes-Generic			
CLEOCIN OVULES (VAGINAL)	2.9%	ON	Yes			
CLINDESSE (VAGINAL)	0.0%	OFF	No			
CLINDAMYCIN (VAGINAL)	8.3%	ON	Yes-Generic			
NUVESSA (VAGINAL)	0.0%	NR	No			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-Kevin IZard
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIFUNGALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
KETOCONAZOLE (ORAL)	0.8%	ON	Yes-Generic			
TERBINAFINE (ORAL)	6.8%	ON	Yes-Generic			
FLUCONAZOLE TABLET (ORAL)	66.2%	ON	Yes-Generic			
NYSTATIN SUSPENSION (ORAL)	17.3%	ON	Yes-Generic			
CLOTRIMAZOLE (MUCOUS MEM)	0.9%	ON	Yes-Generic			
FLUCONAZOLE SUSPENSION (ORAL)	2.7%	ON	Yes-Generic			
NYSTATIN TABLET (ORAL)	0.3%	ON	Yes-Generic			
LAMISIL GRANULES (ORAL)	0.0%	OFF	No			
GRISEOFULVIN ULTRAMICROSIZED (ORAL)	0.0%	OFF	No-Generic			
GRISEOFULVIN SUSPENSION (ORAL)	3.2%	ON	Yes-Generic			
GRIS-PEG (ORAL)	0.2%	ON	Yes-Generic			
GRIFULVIN V TABLETS (ORAL)	0.0%	OFF	No-Generic			
NYSTATIN POWDER (ORAL)	0.2%	ON	Yes-Generic			
GRISEOFULVIN TABLETS (ORAL)	0.3%	ON	No-Generic			
ORAVIG (BUCCAL)	0.0%	OFF	No			
ONMEL (ORAL)	0.0%	OFF	No			
SPORANOX SOLUTION (ORAL)	0.1%	OFF	No			
ITRACONAZOLE (ORAL)	0.6%	ON	Yes-Generic			
NOXAFIL SUSPENSION (ORAL)	0.0%	OFF	No			
VFEND SUSPENSION (ORAL)	0.0%	OFF	No			
VORICONAZOLE TABLETS (ORAL)	0.1%	OFF	No-Generic			
VORICONAZOLE SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
NOXAFIL TABLET (ORAL)	0.0%	OFF	No			
FLUCYTOSINE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIVIRALS, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ACYCLOVIR TABLET (ORAL)	15.0%	ON	Yes-Generic			
ACYCLOVIR CAPSULE (ORAL)	2.3%	ON	Yes-Generic			
VALACYCLOVIR (ORAL)	44.2%	ON	Yes-Generic			
FAMCICLOVIR (ORAL)	0.1%	OFF	No-Generic			
ACYCLOVIR SUSPENSION (ORAL)	1.3%	ON	Yes-Generic			
SITAVIG (BUCCAL)	0.0%	NR	No			
RELENZA (INHALATION)	0.0%	ON	Yes			
TAMIFLU CAPSULE (ORAL)	21.1%	ON	Yes			
RIMANTADINE (ORAL)	0.0%	ON	Yes-Generic			
TAMIFLU SUSPENSION (ORAL)	16.0%	ON	Yes			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

CEPHALOSPORINS AND RELATED ANTIBIOTICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CEFPROZIL TABLET (ORAL)	0.7%	ON	Yes-Generic			
CEFUROXIME TABLET (ORAL)	3.8%	ON	Yes-Generic			
CEFPROZIL SUSPENSION (ORAL)	1.5%	ON	Yes-Generic			
CEFACTOR CAPSULE (ORAL)	0.0%	ON	Yes-Generic			
CEFTIN SUSPENSION (ORAL)	0.4%	ON	Yes			
CEFACTOR SUSPENSION (ORAL)	0.0%	ON	Yes-Generic			
CEFACTOR TABLET ER (ORAL)	0.0%	OFF	No-Generic			
SUPRAX CAPSULE (ORAL)	0.3%	ON	Yes			
SUPRAX SUSPENSION (ORAL)	0.2%	ON	Yes-Generic			
SUPRAX TABLET (ORAL)	0.2%	ON	Yes-Generic			
CEDAX CAPSULE (ORAL)	0.0%	OFF	No			
CEFDINIR CAPSULE (ORAL)	4.6%	ON	Yes-Generic			
SUPRAX TAB CHEW (ORAL)	0.0%	OFF	No-Generic			
CEFDITOREN (AG) (ORAL)	0.0%	OFF	No-Generic			
CEFDINIR SUSPENSION (ORAL)	14.6%	ON	Yes-Generic			
CEDAX SUSPENSION (ORAL)	0.0%	OFF	No			
CEFPODOXIME SUSPENSION (ORAL)	0.0%	OFF	No-Generic			
CEFTIBUTEN CAPSULE (AG) (ORAL)	0.0%	OFF	No-Generic			
CEFPODOXIME TABLET (ORAL)	0.0%	OFF	No-Generic			
CEFTIBUTEN SUSPENSION (AG) (ORAL)	0.0%	OFF	No-Generic			
CEPHALEXIN CAPSULE (ORAL)	21.6%	ON	Yes-Generic			
CEFADROXIL CAPSULE (ORAL)	1.4%	ON	Yes-Generic			
AMOXICILLIN/CLAV TABLET (ORAL)	28.5%	ON	Yes-Generic			
AUGMENTIN 125 SUSPENSION (ORAL)	0.0%	ON	Yes			
AMOXICILLIN/CLAV SUSPENSION (ORAL)	16.0%	ON	Yes-Generic			
AMOXICILLIN/CLAV CHEW TABLET (ORAL)	0.4%	ON	Yes-Generic			
CEPHALEXIN SUSPENSION (ORAL)	5.4%	ON	Yes-Generic			
CEPHALEXIN TABLET (ORAL)	0.0%	ON	Yes-Generic			
CEFADROXIL TABLET (ORAL)	0.0%	ON	Yes-Generic			
CEFADROXIL SUSPENSION (ORAL)	0.3%	ON	Yes-Generic			
AMOXICILLIN/CLAV XR (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

PENICILLINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMOXICILLIN TABLET (ORAL)	10.2%	ON	Yes-Generic			
AMOXICILLIN CAPSULE (ORAL)	25.5%	ON	Yes-Generic			
AMOXICILLIN SUSPENSION (ORAL)	50.2%	ON	Yes-Generic			
PENICILLIN V POTASSIUM TABLET (ORAL)	10.1%	ON	Yes-Generic			
AMPICILLIN CAPSULE (ORAL)	0.2%	ON	Yes-Generic			
PENICILLIN V POTASSIUM SUSPENSION (ORAL)	1.7%	ON	Yes-Generic			
AMOXICILLIN TAB CHEW (ORAL)	1.5%	ON	Yes-Generic			
DICLOXACILLIN (ORAL)	0.6%	ON	Yes-Generic			
AMOXICILLIN ER TABLET (AG) (ORAL)	0.0%	NR	No-Generic			
MOXATAG (ORAL)	0.0%	OFF	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Kevin Izard
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

FLUOROQUINOLONES, ORAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CIPROFLOXACIN TABLET (ORAL)	61.9%	ON	Yes-Generic			
LEVOFLOXACIN TABLET (ORAL)	37.7%	ON	Yes-Generic			
CIPROFLOXACIN ER (ORAL)	0.0%	OFF	No-Generic			
AVELOX (ORAL)	0.0%	OFF	No			
FACTIVE (ORAL)	0.0%	OFF	No-Generic			
CIPRO SUSPENSION (ORAL)	0.1%	OFF	No			
CIPROFLOXACIN SUSPENSION (ORAL)	0.1%	OFF	No-Generic			
MOXIFLOXACIN (AG) (ORAL)	0.0%	OFF	No-Generic			
LEVOFLOXACIN SOLUTION (ORAL)	0.1%	OFF	No-Generic			
MOXIFLOXACIN (ORAL)	0.1%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

MACROLIDES/KETOLIDES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AZITHROMYCIN TABLET (ORAL)	65.1%	ON	Yes-Generic			
AZITHROMYCIN PACKET (ORAL)	0.5%	ON	Yes-Generic			
AZITHROMYCIN SUSPENSION (ORAL)	31.2%	ON	Yes-Generic			
ZMAX (ORAL)	0.0%	OFF	No			
KETEK (ORAL)	0.0%	OFF	No			
CLARITHROMYCIN ER (ORAL)	0.0%	OFF	No-Generic			
CLARITHROMYCIN TABLET (ORAL)	2.1%	ON	Yes-Generic			
CLARITHROMYCIN SUSPENSION (ORAL)	0.4%	ON	Yes-Generic			
ERYTHROMYCIN BASE CAPSULE DR (ORAL)	0.0%	OFF	No-Generic			
ERYTHROCIN (ORAL)	0.1%	ON	Yes-Generic			
ERYTHROMYCIN BASE TABLET (ORAL)	0.5%	ON	Yes-Generic			
E.E.S. 400 TABLET (ORAL)	0.1%	ON	Yes-Generic			
E.E.S. 200 SUSPENSION (ORAL)	0.1%	ON	Yes-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second-Roseanne Barber
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

TETRACYCLINES						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE BRAND (ORAL)	0.6%	ON	Yes-Generic			
VIBRAMYCIN SUSPENSION (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE (ORAL)	3.4%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE 100 MG CAPSULE (ORAL)	49.4%	ON	Yes-Generic			
MINOCYCLINE CAPSULES (ORAL)	26.2%	ON	Yes-Generic			
ORACEA (ORAL)	0.0%	OFF	No			
DOXYCYCLINE HYCLATE TABLET (ORAL)	0.4%	ON	Yes-Generic			
DOXYCYCLINE HYCLATE CAPSULE (ORAL)	0.1%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 50 MG CAPSULE BRAND (ORAL)	0.1%	ON	Yes-Generic			
DOXYCYCLINE MONOHYDRATE TABLET (ORAL)	18.6%	ON	Yes-Generic			
DOXYCYCLINE HYCLATE TABLET (ORAL)	0.1%	OFF	No-Generic			
VIBRAMYCIN SYRUP (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE SUSPENSION (ORAL)	0.1%	OFF	No-Generic			
MINOCYCLINE TABLETS (ORAL)	0.0%	OFF	No-Generic			
MINOCYCLINE ER (ORAL)	0.0%	OFF	No-Generic			
TETRACYCLINE (ORAL)	0.7%	ON	No-Generic			
DOXYCYCLINE HYCLATE TABLET DR (ORAL)	0.0%	NR	No-Generic			
DEMECLOCYCLINE (ORAL)	0.2%	OFF	No-Generic			
DOXYCYCLINE MONOHYDRATE 150 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			
DORYX (ORAL)	0.0%	OFF	No			
DOXYCYCLINE MONOHYDRATE 75 MG CAPSULE (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Michael Witkovsky made a motion to accept staff recommendations as presented.
 - Second-Catherine Decker
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ACNE AGENTS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BENZAFLIN W/PUMP (TOPICAL)	0.0%	OFF	No			
BENZOYL PEROXIDE LOTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
BENZOYL PEROXIDE 10% CREAM OTC (TOPICAL)	0.0%	ON	Yes-Generic			
BENZOYL PEROXIDE 5% WASH OTC (TOPICAL)	2.5%	ON	Yes-Generic			
ATRALIN (TOPICAL)	0.0%	OFF	No			
ACANYA W/PUMP (TOPICAL)	0.0%	OFF	No			
BENZOYL PEROXIDE 10% WASH OTC (TOPICAL)	2.5%	ON	Yes-Generic			
BENZOYL PEROXIDE GEL OTC (TOPICAL)	9.2%	ON	Yes-Generic			
AZELEX (TOPICAL)	1.2%	ON	Yes			
SULFACETAMIDE / SULFUR CLEANSER (TOPICAL)	0.1%	OFF	Yes-Generic			
EPIDUO (TOPICAL)	4.7%	ON	Yes			
RETIN-A CREAM (TOPICAL)	0.0%	OFF	No-Generic			
DESQUAM-X OTC (TOPICAL)	0.0%	ON	Yes			
BENZAMYCIN (TOPICAL)	0.0%	OFF	No			
DIFFERIN LOTION (TOPICAL)	0.2%	ON	Yes			
DIFFERIN GEL (TOPICAL)	8.1%	ON	Yes			
ZIANA (TOPICAL)	0.1%	OFF	No			
AVITA CREAM (TOPICAL)	0.0%	OFF	No			
DIFFERIN CREAM (TOPICAL)	3.8%	ON	Yes			
DIFFERIN GEL PUMP (TOPICAL)	0.8%	ON	Yes			
TAZORAC GEL (TOPICAL)	0.1%	OFF	No			
ERYTHROMYCIN SOLUTION (TOPICAL)	1.3%	ON	Yes-Generic			
KLARON (TOPICAL)	0.0%	OFF	No			
BENZAFLIN (TOPICAL)	0.0%	OFF	No			
TAZORAC CREAM (TOPICAL)	0.3%	OFF	No			
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	0.1%	OFF	No-Generic			
CLINDAMYCIN PHOSPHATE SOLUTION (TOPICAL)	6.7%	ON	Yes-Generic			
SULFACETAMIDE SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
CLINDAMYCIN PHOSPHATE LOTION (TOPICAL)	11.2%	ON	Yes-Generic			
BENZOYL PEROXIDE GEL (TOPICAL)	0.0%	ON	No-Generic			
CLINDAMYCIN PHOSPHATE GEL (TOPICAL)	22.3%	ON	Yes-Generic			
BENZOYL PEROXIDE CLEANSER (TOPICAL)	0.0%	ON	No-Generic			
SULFACETAMIDE CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
TRETINOIN CREAM (TOPICAL)	18.5%	ON	Yes-Generic			
TRETINOIN GEL (TOPICAL)	4.5%	ON	Yes-Generic			
SULFACETAMIDE SODIUM/SULFUR (TOPICAL)	0.0%	OFF	No-Generic			
BENZOYL PEROXIDE FOAM (TOPICAL)	0.0%	OFF	No-Generic			
CLINDAMYCIN / BENZOYL PEROXIDE (DUAC) (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE / SULFUR SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
SULFACETAMIDE / SULFUR / UREA CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
ERYTHROMYCIN GEL (TOPICAL)	0.8%	ON	Yes-Generic			
SULFACETAMIDE / SULFUR LOTION (TOPICAL)	0.0%	OFF	No-Generic			
ACZONE (TOPICAL)	0.3%	OFF	No			
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% (AG) (TOPICAL)	0.1%	OFF	No-Generic			
ADAPALENE CREAM (TOPICAL)	0.0%	OFF	No-Generic			
ADAPALENE GEL (AG) (TOPICAL)	0.0%	OFF	No-Generic			
ADAPALENE GEL (TOPICAL)	0.0%	OFF	No-Generic			
ADAPALENE GEL PUMP (AG) (TOPICAL)	0.0%	OFF	No-Generic			
VELTIN (TOPICAL)	0.0%	OFF	No			
ONEXTON W/PUMP (TOPICAL)	0.0%	OFF	No			
BP 10-1 (TOPICAL)	0.0%	OFF	No-Generic			
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% PUMP (AG) (TOPICAL)	0.0%	OFF	No-Generic			
RETIN-A MICRO 0.04%, 0.1% (TOPICAL)	0.2%	OFF	No			
CLINDAMYCIN / BENZOYL PEROXIDE (BENZAFLIN) (TOPICAL)	0.2%	OFF	No-Generic			
CLINDAMYCIN PHOSPHATE FOAM (TOPICAL)	0.0%	OFF	No-Generic			
AVAR CLEANSER (TOPICAL)	0.0%	OFF	No-Generic			
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% (TOPICAL)	0.1%	OFF	No-Generic			
FABIOR (TOPICAL)	0.0%	OFF	No			
OVACE PLUS WASH (TOPICAL)	0.0%	OFF	No			
TRETINOIN MICROSPHERES GEL 0.04%, 0.1% PUMP (TOPICAL)	0.0%	OFF	No-Generic			
RETIN-A MICRO 0.08% PUMP (TOPICAL)	0.0%	OFF	No			
CLINDAGEL (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second-Pat Towers
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIBIOTICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
NEOMYCIN / POLYMYXIN / PRAMOXINE OTC (TOPICAL)	0.1%	ON	Yes-Generic			
DOUBLE ANTIBIOTIC OINTMENT OTC (TOPICAL)	0.0%	ON	Yes-Generic			
TRIPLE ANTIBIOTIC OINTMENT OTC (TOPICAL)	9.4%	ON	Yes-Generic			
TRIPLE ANTIBIOTIC OTC (TOPICAL)	0.0%	ON	Yes-Generic			
BACITRACIN OTC (TOPICAL)	6.4%	ON	Yes-Generic			
BACITRACIN/POLYMYXIN OTC (TOPICAL)	0.7%	ON	Yes-Generic			
BACTROBAN CREAM (TOPICAL)	0.0%	OFF	No			
MUPIROCIIN OINTMENT (TOPICAL)	82.9%	ON	Yes-Generic			
GENTAMICIN CREAM (TOPICAL)	0.0%	OFF	No-Generic			
MUPIROCIIN CREAM (AG) (TOPICAL)	0.0%	OFF	No-Generic			
MUPIROCIIN CREAM (TOPICAL)	0.2%	OFF	No-Generic			
GENTAMICIN OINTMENT (TOPICAL)	0.2%	OFF	No-Generic			
ALTABAX (TOPICAL)	0.0%	OFF	No			
CENTANY (TOPICAL)	0.0%	OFF	No			

- Discussion: None
- Roseanne Barber made a motion to accept staff recommendations as presented.
 - Second-William Radeuge
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANTIFUNGALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
TOLNAFTATE SOLUTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
MICONAZOLE CREAM OTC (TOPICAL)	2.1%	ON	Yes-Generic			
TOLNAFTATE POWDER OTC (TOPICAL)	0.1%	ON	Yes-Generic			
TOLNAFTATE CREAM OTC (TOPICAL)	0.1%	ON	Yes-Generic			
CLOTRIMAZOLE CREAM RX (TOPICAL)	12.3%	ON	Yes-Generic			
LOTRIMIN AF CREAM OTC (TOPICAL)	0.0%	ON	Yes-Generic			
CLOTRIMAZOLE CREAM OTC (TOPICAL)	6.6%	ON	Yes-Generic			
MICONAZOLE OINT OTC (TOPICAL)	0.1%	ON	Yes-Generic			
MICONAZOLE POWDER OTC (TOPICAL)	0.7%	ON	Yes-Generic			
ALEVAZOL OTC (TOPICAL)	0.0%	ON	Yes			
CLOTRIMAZOLE SOLUTION OTC (TOPICAL)	0.0%	ON	Yes-Generic			
CICLOPIROX CREAM (TOPICAL)	0.0%	OFF	No-Generic			
ERTACZO (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE SHAMPOO (TOPICAL)	12.2%	ON	Yes-Generic			
EXELDERM CREAM (TOPICAL)	0.0%	OFF	No			
NYSTATIN OINT (TOPICAL)	8.6%	ON	Yes-Generic			
EXELDERM SOLUTION (TOPICAL)	0.0%	OFF	No			
CICLOPIROX SUSPENSION (TOPICAL)	0.0%	OFF	No-Generic			
NYSTATIN CREAM (TOPICAL)	19.3%	ON	Yes-Generic			
CLOTRIMAZOLE SOLUTION RX (TOPICAL)	0.4%	ON	Yes-Generic			
CICLOPIROX SOLUTION (TOPICAL)	0.1%	OFF	Yes-Generic			
MENTAX (TOPICAL)	0.0%	OFF	No			
KETOCONAZOLE CREAM (TOPICAL)	11.9%	ON	Yes-Generic			
VUSION (TOPICAL)	0.0%	OFF	No			
CICLOPIROX SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
CICLOPIROX GEL (TOPICAL)	0.0%	OFF	No-Generic			
OXISTAT CREAM (TOPICAL)	0.0%	OFF	No			
CLOTRIMAZOLE-BETAMETHASONE CREAM (TOPICAL)	9.8%	ON	Yes-Generic			
NYSTATIN POWDER (TOPICAL)	10.3%	ON	Yes-Generic			
NAFTIN CREAM (TOPICAL)	0.0%	OFF	No			
OXISTAT LOTION (TOPICAL)	0.0%	OFF	No			
ECONAZOLE (TOPICAL)	0.1%	OFF	No-Generic			
NYSTATIN-TRIAMCINOLONE CREAM (TOPICAL)	3.6%	ON	No-Generic			
EXTINA (TOPICAL)	0.0%	OFF	No			
CLOTRIMAZOLE-BETAMETHASONE LOTION (TOPICAL)	0.4%	ON	No-Generic			
NYSTATIN-TRIAMCINOLONE OINT (TOPICAL)	1.1%	ON	No-Generic			
NAFTIN GEL (TOPICAL)	0.0%	OFF	No			
LUZU (TOPICAL)	0.0%	OFF	No			
JUBLIA (TOPICAL)	0.0%	NR	No			
BENSAL HP (TOPICAL)	0.0%	OFF	No-Generic			
KERYDIN (TOPICAL)	0.0%	NR	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Steve Maiké

- o 11 members were in favor of the motion. Alicia Walker abstained.
- o Motion Passes

ANTIPARASITICS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PERMETHRIN OTC (TOPICAL)	22.3%	ON	Yes-Generic			
EURAX CREAM (TOPICAL)	0.3%	ON	Yes			
ULESFIA (TOPICAL)	1.1%	ON	Yes			
NATROBA (TOPICAL)	0.3%	ON	Yes			
SKLICE (TOPICAL)	3.7%	ON	Yes			
LINDANE LOTION (TOPICAL)	0.1%	OFF	No-Generic			
LINDANE SHAMPOO (TOPICAL)	0.0%	OFF	No-Generic			
PERMETHRIN CREAM (TOPICAL)	62.3%	ON	Yes-Generic			
EURAX LOTION (TOPICAL)	0.0%	OFF	No			
MALATHION BRAND (TOPICAL)	9.9%	ON	No-Generic			
OVIDE (TOPICAL)	0.0%	OFF	No-Generic			
SPINOSAD (TOPICAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Radeuge made a motion to accept staff recommendations as presented.
 - o Second-Michael Witkovsky
 - o 11 members were in favor of the motion. Alicia Walker abstained.
 - o Motion Passes

ANTIVIRALS, TOPICAL						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ZOVIRAX CREAM (TOPICAL)	29.5%	ON	Yes			
DENAVIR (TOPICAL)	1.3%	OFF	No			
XERESE (TOPICAL)	0.2%	OFF	No			
ZOVIRAX OINTMENT (TOPICAL)	1.9%	OFF	Yes			
ACYCLOVIR OINTMENT (TOPICAL)	67.1%	ON	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - o Second-John Fangman
 - o 11 members were in favor of the motion. Alicia Walker abstained.
 - o Motion Passes

MISCELLANEOUS ANALGESICS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ASPIRIN TABLET OTC (ORAL)	71.7%	ON	Yes-Generic			
ASPIRIN TAB CHEW OTC (ORAL)	24.8%	ON	Yes-Generic			
BAYER CHEWABLE OTC (ORAL)	0.0%	ON	Yes			
ACETAMINOPHEN / BUTALBITAL (ORAL)	0.1%	OFF	No-Generic			
BUTALBITAL / APAP / CAFFEINE (ORAL)	3.4%	OFF	No-Generic			
BUPAP (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - o Second-Catherine Decker
 - o 11 members were in favor of the motion. Alicia Walker abstained.
 - o Motion Passes

ANALGESICS, NARCOTICS LONG						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
METHADONE TABLET (ORAL)	13.8%	ON	Yes-Generic			
METHADONE SOL TABLET (ORAL)	0.0%	ON	Yes-Generic			
METHADONE CONC (ORAL)	11.9%	ON	Yes-Generic			
METHADONE SOLUTION (ORAL)	0.2%	ON	Yes-Generic			
KADIAN (ORAL)	0.5%	ON	Yes			
MORPHINE ER TABLET (ORAL)	32.8%	ON	Yes-Generic			
FENTANYL (TRANSDERM)	19.2%	ON	Yes-Generic			
BUTRANS (TRANSDERM)	4.4%	ON	Yes			
TRAMADOL ER (ORAL)	0.3%	OFF	No-Generic			
OXYCODONE ER (AG) (ORAL)	0.0%	NR	No-Generic			
CONZIP (ORAL)	0.0%	OFF	No			
TRAMADOL ER (GENERIC RYZOLT ER) (ORAL)	0.0%	OFF	No-Generic			
NUCYNTA ER (ORAL)	0.4%	OFF	No			
OXYCONTIN (ORAL)	14.8%	OFF	No			
OPANA ER (ORAL)	0.9%	OFF	No			
OXYMORPHONE ER (ORAL)	0.3%	OFF	No-Generic			
ZOHYDRO ER (ORAL)	0.0%	OFF	No			
MORPHINE ER CAPSULE (AVINZA) (ORAL)	0.0%	OFF	No-Generic			
MORPHINE ER CAPSULE (KADIAN) (ORAL)	0.1%	OFF	No-Generic			
HYSINGLA ER (ORAL)	0.0%	NR	No			
AVINZA (ORAL)	0.0%	OFF	No			
EMBEDA (ORAL)	0.0%	OFF	No			
FENTANYL (37.5, 62.5, 87.5 MG) (TRANSDERM)	0.0%	NR	No-Generic			
HYDROMORPHONE ER (AG) (ORAL)	0.1%	NR	No-Generic			
EXALGO (ORAL)	0.2%	OFF	No			
HYDROMORPHONE ER (ORAL)	0.0%	NR	No-Generic			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-Steve Maike
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ANALGESICS, NARCOTICS SHORT						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
MEPERIDINE SOLUTION (ORAL)	0.0%	OFF	No-Generic			
TRAMADOL (ORAL)	17.1%	ON	Yes-Generic			
APAP / CODEINE ELIXIR (ORAL)	0.5%	ON	Yes-Generic			
DILAUDID LIQUID (ORAL)	0.0%	OFF	No			
APAP / CODEINE TABLET (ORAL)	5.7%	ON	Yes-Generic			
MORPHINE SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
MEPERIDINE TABLET (ORAL)	0.0%	OFF	No-Generic			
HYDROCODONE / APAP TABLET (ORAL)	40.1%	ON	Yes-Generic			
MORPHINE IR TABLET (ORAL)	0.7%	ON	Yes-Generic			
MORPHINE CONC SOLUTION (ORAL)	0.1%	ON	Yes-Generic			
HYDROMORPHONE TABLET (ORAL)	0.7%	ON	Yes-Generic			
HYDROCODONE / IBUPROFEN (ORAL)	0.3%	ON	Yes-Generic			
HYDROCODONE / APAP TABLET (ORAL)	0.0%	OFF	No-Generic			
BUTALBITAL / CAFFEINE / APAP W/CODEINE (ORAL)	0.0%	OFF	No-Generic			
CODEINE (ORAL)	0.1%	ON	Yes-Generic			
OXYCODONE SOLUTION (ORAL)	0.6%	ON	Yes-Generic			
CODEINE SOLUTION (ORAL)	0.0%	ON	Yes-Generic			
OXYCODONE / APAP TABLET (ORAL)	16.4%	ON	Yes-Generic			
TRAMADOL / APAP (ORAL)	0.0%	OFF	No-Generic			
REPREXAIN (ORAL)	0.0%	OFF	No-Generic			
BUTORPHANOL TARTRATE (NASAL)	0.0%	OFF	No-Generic			
OXYCODONE TABLET (ORAL)	17.1%	ON	Yes-Generic			
OXYCODONE / IBUPROFEN (ORAL)	0.0%	OFF	No-Generic			
MORPHINE SUPPOSITORIES (RECTAL)	0.0%	ON	Yes-Generic			
OXYCODONE CAPSULE (ORAL)	0.0%	OFF	No-Generic			
IBUDONE (ORAL)	0.0%	OFF	No-Generic			
HYDROCODONE / APAP SOLUTION (ORAL)	0.3%	ON	Yes-Generic			
NUCYNTA (ORAL)	0.1%	OFF	No			
BUTALBITAL COMPOUND W/CODEINE (ORAL)	0.0%	OFF	No-Generic			
HYCET (ORAL)	0.0%	OFF	No-Generic			
DIHYDROCODEINE / ASA / CAFFEINE (AG) (ORAL)	0.0%	OFF	No-Generic			
HYDROMORPHONE LIQUID (ORAL)	0.0%	OFF	No-Generic			
OXYCODONE / ASA (ORAL)	0.0%	OFF	No-Generic			
CARISOPRODOL COMPOUND-CODEINE (ORAL)	0.0%	OFF	No-Generic			
FIORICET / CODEINE (ORAL)	0.0%	OFF	No-Generic			
LEVORPHANOL (ORAL)	0.0%	OFF	No-Generic			
PENTAZOCINE / NALOXONE (ORAL)	0.0%	OFF	No-Generic			
HYDROMORPHONE SUPPOSITORIES (RECTAL)	0.0%	OFF	No-Generic			
OXYMORPHONE (ORAL)	0.1%	OFF	No-Generic			
CAPITAL W-CODEINE (ORAL)	0.0%	ON	Yes-Generic			
XODOL (ORAL)	0.0%	OFF	No-Generic			
PRIMLEV (ORAL)	0.0%	OFF	No-Generic			
SUBSYS (SUBLINGUAL)	0.0%	OFF	No			
OXYCODONE CONC (ORAL)	0.0%	OFF	No-Generic			
FENTORA (BUCCAL)	0.0%	OFF	No			
ABSTRAL (SUBLINGUAL)	0.0%	OFF	No			
FENTANYL (BUCCAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Pat Towers made a motion to accept staff recommendations as presented.
 - Second-Roseanne Barber
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

OPIATE DEPENDENCE TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SUBOXONE FILM (SUBLINGUAL)	93.3%	ON	Yes			
BUNAVAIL (BUCCAL)	0.0%	OFF	No			
BUPRENORPHINE HCL (SUBLINGUAL)	6.5%	OFF	No-Generic			
ZUBSOLV (SUBLINGUAL)	0.0%	OFF	No			
BUPRENORPHINE/NALOXONE TAB (SUBLINGUAL)	0.1%	OFF	No-Generic			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-John Fangman

- o 11 members were in favor of the motion. Alicia Walker abstained.
- o Motion Passes

ANTIMIGRAINE AGENTS, TRIPTANS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
RELPAX (ORAL)	9.2%	ON	Yes			
IMITREX (NASAL)	2.6%	ON	Yes			
SUMATRIPTAN (ORAL)	63.6%	ON	Yes-Generic			
RIZATRIPTAN ODT (ORAL)	4.1%	ON	Yes-Generic			
TREXIMET (ORAL)	0.1%	OFF	No			
RIZATRIPTAN TABLET (ORAL)	10.5%	ON	Yes-Generic			
IMITREX KIT (SUBCUTANE.)	5.9%	ON	Yes			
NARATRIPTAN (ORAL)	1.8%	OFF	No-Generic			
ZOLMITRIPTAN ODT (ORAL)	0.1%	OFF	No-Generic			
ZOLMITRIPTAN TABLET (ORAL)	0.3%	OFF	No-Generic			
ZOLMITRIPTAN ODT (AG) (ORAL)	0.1%	OFF	No-Generic			
FROVA (ORAL)	0.3%	OFF	No			
ZOMIG (NASAL)	0.2%	OFF	No			
AXERT (ORAL)	0.2%	OFF	No			
ZOLMITRIPTAN TABLET (AG) (ORAL)	0.2%	OFF	No-Generic			
RIZATRIPTAN ODT (AG) (ORAL)	0.4%	ON	Yes-Generic			
SUMAVEL DOSEPRO (SUBCUTANE.)	0.0%	OFF	No			
IMITREX VIAL (SUBCUTANE.)	0.2%	ON	Yes			
SUMATRIPTAN KIT (SUBCUTANE.)	0.0%	OFF	No-Generic			
SUMATRIPTAN (NASAL)	0.1%	OFF	No-Generic			
SUMATRIPTAN DISP SYRIN (SUBCUTANE.)	0.0%	OFF	No-Generic			
SUMATRIPTAN VIAL (SUBCUTANE.)	0.0%	OFF	No-Generic			
SUMATRIPTAN KIT (SUN) (SUBCUTANE.)	0.0%	OFF	No-Generic			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - o Second-William Raduege
 - o 11 members were in favor of the motion. Alicia Walker abstained.
 - o Motion Passes

SKELETAL MUSCLE RELAXANTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
CYCLOBENZAPRINE (ORAL)	57.4%	ON	Yes-Generic			
CARISOPRODOL (ORAL)	1.6%	OFF	No-Generic			
METHOCARBAMOL (ORAL)	5.6%	ON	Yes-Generic			
CHLORZOXAZONE (ORAL)	0.5%	ON	Yes-Generic			
ORPHENADRINE ER (ORAL)	0.1%	OFF	No-Generic			
TIZANIDINE TABLETS (ORAL)	18.9%	ON	Yes-Generic			
BACLOFEN (ORAL)	14.9%	ON	Yes-Generic			
DANTROLENE SODIUM (ORAL)	0.4%	ON	Yes-Generic			
CARISOPRODOL 250 MG (ORAL)	0.1%	OFF	No-Generic			
CARISOPRODOL COMPOUND (ORAL)	0.0%	OFF	No-Generic			
SOMA 250 MG (ORAL)	0.0%	OFF	No			
AMRIX (ORAL)	0.0%	OFF	No			
LORZONE (ORAL)	0.0%	OFF	No-Generic			
TIZANIDINE CAPSULES (ORAL)	0.0%	OFF	No-Generic			
METAXALONE (ORAL)	0.4%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - o Second-Ward Brown
 - o 11 members were in favor of the motion. Alicia Walker abstained.
 - o Motion Passes

BLADDER RELAXANT PREPARATIONS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
OXYTROL (TRANSDERM.)	0.4%	OFF	No			
OXYBUTYNIN SYRUP (ORAL)	1.9%	ON	Yes-Generic			
OXYBUTYNIN TABLET (ORAL)	33.4%	ON	Yes-Generic			
ENABLEX (ORAL)	0.8%	OFF	No			
TOVIAZ (ORAL)	9.2%	ON	Yes			
VESICARE (ORAL)	37.8%	ON	Yes			
GELNIQUE (TRANSDERM.)	0.1%	OFF	No			
OXYBUTYNIN ER (ORAL)	12.1%	ON	Yes-Generic			
GELNIQUE GEL PUMP (TRANSDERMAL)	0.0%	OFF	No			
TROSPIUM (ORAL)	0.2%	OFF	No-Generic			
TOLTERODINE (ORAL)	0.3%	OFF	No-Generic			
TROSPIUM ER (ORAL)	0.2%	OFF	No-Generic			
MYRBETRIQ (ORAL)	2.2%	OFF	No			
TOLTERODINE ER (AG) (ORAL)	0.2%	OFF	No-Generic			
TOLTERODINE ER (ORAL)	0.7%	OFF	No-Generic			
DETROL LA (ORAL)	0.4%	OFF	No			
DETROL (ORAL)	0.1%	OFF	No			

- Discussion: None
- Steve Maike made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

BONE RESORPTION SUPPRESSION AND RELATED AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ALENDRONATE TABLETS (ORAL)	90.2%	ON	Yes-Generic			
ACTONEL (ORAL)	0.9%	OFF	No			
FORTICAL (NASAL)	3.4%	ON	Yes			
BINOSTO (ORAL)	0.0%	OFF	No			
ATELVIA (ORAL)	0.1%	OFF	No			
EVISTA (ORAL)	0.6%	OFF	No			
ALENDRONATE SOLUTION (ORAL)	0.1%	OFF	No-Generic			
FOSAMAX PLUS D (ORAL)	0.1%	OFF	No			
BONIVA (ORAL)	0.1%	OFF	No			
CALCITONIN SALMON (NASAL)	0.4%	OFF	No-Generic			
RISEDRONATE (AG) (ORAL)	0.1%	OFF	No-Generic			
IBANDRONATE TABLETS (ORAL)	1.4%	OFF	No-Generic			
RALOXIFENE (AG) (ORAL)	0.8%	OFF	No-Generic			
RALOXIFENE (ORAL)	1.7%	NR	No-Generic			
RISEDRONATE (ORAL)	0.1%	OFF	No-Generic			
MIACALCIN (NASAL)	0.1%	OFF	No			
ETIDRONATE DISODIUM (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- Catherine Decker made a motion to accept staff recommendations as presented.
 - Second-Michael Witkovsky
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

ERYTHROPOIESIS STIMULATING PROTEINS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
EPOGEN (INJECTION)	0.0%	OFF	No			
ARANESP DISP SYRIN (INJECTION)	22.8%	ON	Yes			
ARANESP VIAL (INJECTION)	9.1%	ON	Yes			
PROCRIT (INJECTION)	68.1%	ON	Yes			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.

- o Motion Passes

GROWTH HORMONE						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
SAIZEN CARTRIDGE (INJECTION)	0.1%	OFF	No			
SAIZEN VIAL (INJECTION)	0.0%	OFF	No			
OMNITROPE CARTRIDGE (INJECTION)	0.0%	OFF	No			
NUTROPIN AQ CARTRIDGE (INJECTION)	7.2%	ON	Yes			
NORDITROPIN PEN (INJECTION)	92.6%	ON	Yes			
TEV-TROPIN VIAL (INJECTION)	0.0%	OFF	No			
OMNITROPE VIAL (INJECTION)	0.0%	OFF	No			
GENOTROPIN DISP SYRIN (INJECTION)	0.0%	OFF	No			
SEROSTIM VIAL (INJECTION)	0.0%	OFF	No			
HUMATROPE VIAL (INJECTION)	0.0%	OFF	No			
ZORBTIVE VIAL (INJECTION)	0.0%	OFF	No			
HUMATROPE CARTRIDGE (INJECTION)	0.1%	OFF	No			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - o Second-William Raduege
 - o 11 members were in favor of the motion. Alicia Walker abstained.
 - o Motion Passes

ANDROGENIC AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
ANDROGEL GEL PACKET (TRANSDERM.)	33.7%	ON	Yes			
ANDRODERM (TRANSDERM)	2.4%	OFF	No			
ANDROGEL GEL PUMP (TRANSDERM)	55.7%	ON	Yes			
AXIRON (TRANSDERM)	0.9%	OFF	No			
TESTOSTERONE GEL PUMP (AG) (VOGELXO) (TRANSDERM)	0.2%	OFF	No-Generic			
TESTOSTERONE GEL PUMP (AG) (ANDROGEL) (TRANSDERM)	0.0%	NR	No-Generic			
TESTOSTERONE GEL (AG) (FORTESTA) (TRANSDERM)	0.0%	NR	No-Generic			
TESTOSTERONE GEL (AG) (VOGELXO) (TRANSDERM)	0.0%	OFF	No-Generic			
FORTESTA (TRANSDERM)	0.0%	OFF	No			
TESTOSTERONE GEL (AG) (TESTIM) (TRANSDERM)	0.4%	OFF	No-Generic			
TESTOSTERONE GEL PACKET (AG) (ANDROGEL) (TRANSDERM)	0.0%	NR	No-Generic			
TESTOSTERONE GEL PACKET (AG) (VOGELXO) (TRANSDERM)	0.0%	OFF	No-Generic			
VOGELXO GEL (TRANSDERM)	0.0%	OFF	No			
VOGELXO GEL PACKET (TRANSDERM)	0.0%	OFF	No			
VOGELXO GEL PUMP (TRANSDERM)	0.0%	OFF	No			
TESTIM (TRANSDERM.)	6.7%	ON	No			

- Discussion: None
- Kevin Izard made a motion to accept staff recommendations as presented.
 - o Second-Steve Maike
 - o 11 members were in favor of the motion. Alicia Walker abstained.
 - o Motion Passes

BPH TREATMENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
FINASTERIDE (ORAL)	21.3%	ON	Yes-Generic			
ALFUZOSIN (ORAL)	1.7%	ON	Yes-Generic			
TERAZOSIN (ORAL)	12.9%	ON	Yes-Generic			
TAMSULOSIN (ORAL)	61.0%	ON	Yes-Generic			
CARDURA XL (ORAL)	0.0%	OFF	No			
AVODART (ORAL)	0.5%	OFF	No			
RAPAFLO (ORAL)	0.4%	OFF	No			
DOXAZOSIN (ORAL)	2.1%	OFF	No-Generic			
JALYN (ORAL)	0.1%	OFF	No			

- Discussion: None
- Ward Brown made a motion to accept staff recommendations as presented.
 - Second-William Radeuge
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

PHOSPHATE BINDERS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PHOSLYRA (ORAL)	0.5%	ON	Yes			
RENVELA TABLET (ORAL)	2.4%	OFF	No			
RENAGEL (ORAL)	53.8%	ON	Yes			
CALCIUM ACETATE TABLET (ORAL)	31.9%	ON	Yes-Generic			
CALCIUM ACETATE CAPSULE (ORAL)	4.5%	OFF	No-Generic			
ELIPHOS (ORAL)	1.1%	ON	Yes			
FOSRENOL (ORAL)	3.6%	OFF	No			
RENVELA POWDER PACK (ORAL)	1.2%	OFF	No			
SEVELAMER CARBONATE TABLET (AG) (ORAL)	1.1%	OFF	No-Generic			
AURYXIA (ORAL)	0.0%	NR	No			
VELPHORO (ORAL)	0.0%	OFF	No			

- Discussion: None
- Lawrence Fleming made a motion to accept staff recommendations as presented.
 - Second-Roseanne Barber
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HEPATITIS B AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
BARACLUDE TABLET (ORAL)	75.3%	ON	Yes			
EPIVIR HBV SOLUTION (ORAL)	0.0%	ON	Yes			
EPIVIR HBV TABLET (ORAL)	20.7%	ON	Yes			
LAMIVUDINE HBV TABLET (AG) (ORAL)	0.0%	OFF	No-Generic			
LAMIVUDINE HBV TABLET (ORAL)	0.0%	OFF	No-Generic			
BARACLUDE SOLUTION (ORAL)	4.0%	ON	Yes			
HEPSERA (ORAL)	0.0%	ON	Yes			
TYZEKA (ORAL)	0.0%	ON	Yes			
ENTECAVIR TABLET (AG) (ORAL)	0.0%	OFF	No-Generic			
ADEFOVIR DIPIVOXIL (ORAL)	0.0%	OFF	No-Generic			
ENTECAVIR TABLET (ORAL)	0.0%	OFF	No-Generic			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-John Fangman
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

HEPATITIS C AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
PEG-INTRON (SUBCUTANE.)	0.0%	ON	Yes			
PEGASYS VIAL (SUBCUTANE.)	4.5%	ON	Yes			
PEGASYS SYRINGE (SUB-Q)	7.5%	ON	Yes			
PEGASYS PROCLICK (SUB-Q)	4.0%	ON	Yes			
OLYSIO (ORAL)	0.0%	OFF	No			
VIEKIRA PAK (ORAL)	0.0%	NR	Yes			
HARVONI (ORAL)	0.0%	NR	No			
SOVALDI (ORAL)	14.9%	OFF	No			
RIBAVIRIN CAPSULE (ORAL)	21.9%	ON	Yes-Generic			
RIBAVIRIN TABLET (ORAL)	47.3%	ON	Yes-Generic			
RIBASPHERE 400 MG (ORAL)	0.0%	OFF	No-Generic			
REBETOL SOLUTION (ORAL)	0.0%	OFF	No			
RIBASPHERE 600 MG (ORAL)	0.0%	OFF	No-Generic			
RIBAPAK (ORAL)	0.0%	OFF	No-Generic			
RIBAVIRIN DOSE PACK (ORAL)	0.0%	OFF	No-Generic			

Discussion: John Fangman was struck by the presentation from the clinician's testimony. John Fangman was comfortable with the recommendations. However, he added since this is such a dynamic time for Hepatitis C treatment, he would recommend revisiting this category in November as well as a report of our treatment experience. He would also propose a panel of Hepatitis C specialists to work in collaboration with the department. James Boblin asked if the doctors prescribing currently are limited to gastroenterology and infectious disease doctors. Catherine Decker stated that she appreciated the inputs from James Boblin and John Fangman and wanted to make sure the process can be less burdensome for the providers if Viekira Pak is not the right choice for the patient. Staff clarified that all drugs in the hepatitis c agents drug class will still require clinical prior authorization. Steve Maike added that compliance is very important with these drugs, especially Viekira Pak, and the additional pill burden. Any savings could be wiped out with non-compliance. Kevin Izard inquired about the geographic access to Hepatitis C specialists in WI. He suggested maybe we could only require a specialist consult to get the drugs approved. John Fangman added that management of these products is complex. In addition, he felt that they needed to be managed by specialists and that there is support out there to assist access in rural areas, such as Telehealth and Project Echo. James Boblin asked if there is a mechanism in place to review for compliance. Lynn Radmer added that the prior authorizations are approved for 8 weeks initially and follow up consists of a call to the prescriber or pharmacy to obtain a 4 week viral count prior to extending the prior authorization longer. Lora Wiggins stated that the state is tracking our member's success rate. The state has a very high touch process.

Motion 1:

- Roseanne Barber made a motion to accept staff recommendations as presented.
 - Second-William Raduege
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion 1 passes

Motion 2:

- John Fangman made a motion to revisit the Hepatitis C class in 6 months and to request that the department report back to the committee information on the utilization of Viekira Pak, adherence, toxicity, and early markers of treatment response. John Fangman also stated that he would like to see a group of Hepatitis C prescribers experienced in Hepatitis C management work with the department regarding future decisions.
 - Second-Pat Towers
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion 2 passes

MULTIPLE SCLEROSIS AGENTS						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
COPAXONE SYRINGE KIT (SUBCUTANE.)	30.0%	ON	Yes			
AVONEX PEN (INTRAMUSC)	11.9%	ON	Yes			
AVONEX (INTRAMUSC.)	9.1%	ON	Yes			
REBIF (SUBCUTANE.)	7.4%	ON	Yes			
REBIF REBIDOSE PEN INJCTR (SUBCUTANE.)	3.3%	ON	Yes			
BETASERON KIT (SUBCUTANE.)	4.8%	ON	Yes			
AMPYRA (ORAL)	6.7%	OFF	No			
EXTAVIA KIT (SUBCUTANE.)	0.1%	ON	No			
EXTAVIA VIAL (SUBCUTANE.)	0.0%	ON	No			
AUBAGIO (ORAL)	2.4%	OFF	Yes			
GILENYA (ORAL)	5.7%	OFF	Yes			
COPAXONE SYRINGE (SUBCUTANE.)	4.1%	OFF	Yes			
TECFIDERA (ORAL)	14.5%	OFF	No			
PLEGRIDY (SUBCUTANE.)	0.1%	NR	No			

- Discussion: None
- James Boblin made a motion to accept staff recommendations as presented.
 - Second-Ward Brown
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes

GI MOTILITY, CHRONIC						
Brand Name	Current Market Share	Current PDL Status	PDL Recommendation	COMMITTEE RECOMMENDATIONS	STATE MODIFICATIONS	SECRETARY MODIFICATIONS
AMITIZA (ORAL)	36.3%	ON	Yes			
LINZESS (ORAL)	62.8%	ON	Yes			
MOVANTIK (ORAL)	0.0%	NR	Yes			
LOTRONEX (ORAL)	0.9%	OFF	No			

- Discussion: None
- William Raduege made a motion to accept staff recommendations as presented.
 - Second-Pat Towers
 - 11 members were in favor of the motion. Alicia Walker abstained.
 - Motion Passes